Alnylam, Isis form research venture
From Times Wire Services
Alnylam Pharmaceuticals Inc. and Isis Pharmaceuticals Inc. have formed a venture uniting Nobel Prize winners David Baltimore and Phillip Sharp to create drugs from a newly discovered class of genetic material.
The venture, Regulus Therapeutics, will have exclusive licenses from Alnylam and Isis for technology focused on so-called microRNAs. The molecules regulate networks of genes that may be involved in diseases including cancer, viral infections and metabolic disorders, the companies said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
